Caroline Litchfield - Merck Ex CFO
| 6MK Stock | EUR 95.80 1.20 1.24% |
Insider
Caroline Litchfield is Ex CFO of Merck Co
| Age | 54 |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1196 % which means that it generated a profit of $0.1196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3446 %, meaning that it generated $0.3446 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Schinecker | Roche Holding Ltd | 48 | |
| Minoru Kikuoka | Astellas Pharma | N/A | |
| Jonathan Graham | Amgen Inc | 62 | |
| Peter Griffith | Amgen Inc | 64 | |
| Chihiro Yokota | Astellas Pharma | N/A | |
| Yoshitsugu Shitaka | Astellas Pharma | N/A | |
| Stig Ogata | Astellas Pharma | N/A | |
| Gabriel Harnier | Bayer Aktiengesellschaft | 52 | |
| Rodrigo Santos | Bayer Aktiengesellschaft | 50 | |
| Catherine Levitt | Astellas Pharma | N/A | |
| Robert Bradway | Amgen Inc | 60 | |
| Bruno Eschli | Roche Holding Ltd | N/A | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Barbara Schadler | Roche Holding Ltd | 61 | |
| Naoki BSc | Astellas Pharma | N/A | |
| William Anderson | Roche Holding Ltd | 57 | |
| Arvind Sood | Amgen Inc | N/A | |
| Heiko Schipper | Bayer Aktiengesellschaft | 54 | |
| Sarena Lin | Bayer Aktiengesellschaft | 52 | |
| Frank Lohner | Amgen Inc | 54 | |
| Katsuyoshi Sugita | Astellas Pharma | N/A | |
Management Performance
| Return On Equity | 0.34 | |||
| Return On Asset | 0.12 |
Merck Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, Exec Counsel | ||
| David Williams, Ex Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Lisa LeCointeCephas, VP Officer | ||
| Richard DeLuca, Ex Health | ||
| Kenneth Frazier, Ex Chairman | ||
| Peter Dannenbaum, VP Relations | ||
| Robert JD, Pres Chairman | ||
| Jennifer Mauer, VP Communications |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.34 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 286.52 B | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.09 % | |||
| Shares Owned By Institutions | 77.66 % | |||
| Price To Earning | 31.84 X | |||
| Price To Book | 6.30 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Merck Stock
Merck financial ratios help investors to determine whether Merck Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Merck with respect to the benefits of owning Merck security.